Definitive Radiotherapy With SBRT or IMRT Boost for Breast Cancer: Excellent Local Control and Cosmetic Outcome

Shibamoto, Yuta; Murai, Taro; Suzuki, Kazushi; Hashizume, Chisa; Ohta, Kengo; Yamada, Yoshiaki; Niwa, Masanari; Torii, Akihiro

doi:10.1177/1533033818799355

Cited by 24 publications

(27 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Regarding radical SBRT, there are even fewer reports. Shibamoto et al reported that they performed whole breast irradiation and SBRT boost with the radiosensitizer KORTUC [ 20 ] for 18 patients who refused surgery, and only one case developed local recurrence [ 21 ]. Barry et al [ 22 ] reviewed SBRT for breasts and reported that five neoadjuvant setting phase I/II trials were underway, including the ARTEMIS trial in Canada and the ABLATIVE trial in the Netherlands.…”

Section: Discussionmentioning

confidence: 99%

A clinical study of curative partial breast irradiation for stage I breast cancer using carbon ion radiotherapy

et al. 2020

View full text Add to dashboard Cite

Background and purpose Our institute initiated carbon ion radiotherapy research for patients with stage I breast cancer in April 2013. The purpose of this article is to evaluate the treatment outcome of cases treated outside clinical trial up to May 2020. Materials and methods Eligibility criteria of the patients were having untreated stage I breast cancer and being unsuitable for operation for physical or mental reasons. The irradiated volume was defined as the gross tumor including intraductal components. The dose escalation study was initially conducted four times a week for a total of 52.8 Gy [relative biological efficacy (RBE)]. After confirming that adverse effects were within acceptable range, the total dose was increased to 60.0 Gy (RBE). Results Between April 2013 and November 2015, 14 cases were treated. The median follow up period was 61 months. No adverse toxicities were observed except for grade 1 acute skin reaction in 10 cases. The time required from carbonion radiotherapy to tumor disappearance was 3 months in 1 case, 6 months in 3 cases, 12 months in 4 cases, and 24 months in 5 cases. The third case developed local recurrence 6 months after radiotherapy. Twelve patients with luminal subtype received 5-year endocrine therapy. Thirteen of 14 tumors have been maintaining complete response with excellent cosmetic results. Conclusions The time from carbon ion radiotherapy to tumor disappearance was longer than expected, but complete tumor disappearance was observed except for one high-grade case. With careful patient selection, carbonion radiotherapy in patients with stage I breast cancer is deemed effective and safe, and further research is recommended.

show abstract

Section: Discussionmentioning

confidence: 99%

A clinical study of curative partial breast irradiation for stage I breast cancer using carbon ion radiotherapy

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Regarding radical SBRT, there are even fewer reports. Shibamoto et al reported that they performed whole breast irradiation and SBRT boost with the radiosensitizer KORTUC 20 for 18 patients who refused surgery, and only one case developed local recurrence 21 . Barry et al reviewed SBRT for breasts and reported that ve neoadjuvant setting phase I / II trials were underway, including the ARTEMIS trial in Canada and the ABLATIVE trial in the Netherlands 22 .…”

Section: Discussionmentioning

confidence: 99%

A clinical study of curative partial breast irradiation for stage I breast cancer using carbon ion radiotherapy

Karasawa¹,

Omatsu

Shiba

et al. 2020

Preprint

View full text Add to dashboard Cite

Background and purpose: Our institute initiated carbon ion radiotherapy research for patients with stage I breast cancer in April 2013. The purpose of this article is to evaluate the treatment outcome of cases treated outside clinical trial up to May 2020.Materials and methods: Eligibility criteria of the patients were having untreated stage I breast cancer and being unsuitable for operation for physical or mental reasons. The irradiated volume was defined as the gross tumor including intraductal components. The dose escalation study was initially conducted four times a week for a total of 52.8 Gy ([Relative Biological Efficacy (RBE)]). After confirming that adverse effects were within acceptable range, the total dose was increased to 60.0 Gy (RBE). Results: Between April 2013 and November 2015, 14 cases were treated. The median follow up period was 61 months. No adverse toxicities were observed except for grade 1 acute skin reaction in 10 cases. The time required from carbon-ion radiotherapy to tumor disappearance was 3 months in 1 case, 6 months in 3 cases, 12 months in 4 cases, and 24 months in 5 cases. The third case developed local recurrence 6 months after radiotherapy. Twelve patients with luminal subtype received 5-year endocrine therapy. Thirteen of 14 tumors have been maintaining complete response with excellent cosmetic results.Conclusions: The time from carbon ion radiotherapy to tumor disappearance was longer than expected, but complete tumor disappearance was observed except for one high-grade case. With careful patient selection, carbon-ion radiotherapy in patients with stage I breast cancer is deemed effective and safe, and further research is recommended.

show abstract

“…In lung cancer, for example, it is now the standard treatment option for early-stage inoperable non-small cell lung cancer due to its superior e cacy. [9] Likewise, SBRT plays an important role in hepatopulmonary metastases from colon and breast cancers [10][11] . For patients with recurrence and metastasis, several small, single-institution retrospective studies have shown that SBRT has a relatively high local control rate and low toxicity in the treatment of sarcoma PM [19][20][21] .…”

Section: Discussionmentioning

confidence: 99%

Stereotactic Body Radiotherapy for Metastatic and Recurrent Soft Tissue Sarcoma

Feng¹,

Li²,

Li³

et al. 2020

Preprint

View full text Add to dashboard Cite

BackgroundSoft tissue sarcoma（STS） is a malignant tumor of highly heterogeneous mesenchymal origin. STS has a biologic pattern and clinical transformation with localized invasive growth and susceptibility to hematogenous metastasis. Metastatic and recurrent soft tissue sarcoma may be treated by local therapeutic options, including surgery and radiation therapy. This study evaluated the safety and efficacy of SBRT for metastatic and recurrent soft tissue sarcoma.MethodsWe performed a retrospective analysis of 37 STS patients with 58 lesions treated with SBRT from 2009-2019 at our institution. We analyze the local control (LC), overall survival (OS), progression free survival (PFS) and toxicity rates of the patients.ResultThe median follow-up was 20 months（range 2 to 120 months）. One and two year LC rates were 75.3% and 55.2% [95% confidence interval (CI) 20–25 months]. Median OS was 24 months and the survival rates were 66.6%, 45% and 26.6% at 1, 2 and 3-year after SBRT. Median PFS were 11months (95% CI 8–18 months). No acute or chronic grade ≥ 3 toxicity was observed.ConclusionsIn patients with metastatic and recurrent STS, LC, OS and PFS were higher than expected. SBRT should be a proper treatment option for STS.

show abstract

Definitive Radiotherapy With SBRT or IMRT Boost for Breast Cancer: Excellent Local Control and Cosmetic Outcome

Cited by 24 publications

References 26 publications

A clinical study of curative partial breast irradiation for stage I breast cancer using carbon ion radiotherapy

A clinical study of curative partial breast irradiation for stage I breast cancer using carbon ion radiotherapy

A clinical study of curative partial breast irradiation for stage I breast cancer using carbon ion radiotherapy

Stereotactic Body Radiotherapy for Metastatic and Recurrent Soft Tissue Sarcoma

Contact Info

Product

Resources

About